Compare HOUR & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HOUR | ACET |
|---|---|---|
| Founded | 2015 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.3M | 93.5M |
| IPO Year | 2022 | N/A |
| Metric | HOUR | ACET |
|---|---|---|
| Price | $2.02 | $0.52 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 106.3K | ★ 1.9M |
| Earning Date | 11-12-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $140,790,433.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $85.48 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.10 | $0.45 |
| 52 Week High | $6.90 | $1.12 |
| Indicator | HOUR | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 47.62 | 34.97 |
| Support Level | $2.01 | $0.53 |
| Resistance Level | $2.24 | $0.57 |
| Average True Range (ATR) | 0.11 | 0.05 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 53.13 | 20.77 |
Hour Loop Inc is a technology-enabled consumer products company that uses machine learning and data analytics to design, develop, market, and sell products. Hour Loop predominantly operates through online retail channels such as Amazon, Walmart, and Hourloop.com. The Company, as an Internet marketplace seller, sells products in multiple categories, including home/garden decor, toys, kitchenware, apparel, and electronics. It has only one segment, which is online retail (e-commerce).
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.